Comparison of Dyslipidemia Among Diabetics Versus Non Diabetics in

Status Not yet recruiting

Clinical Trial Summary

- How dyslipidemia common among Diabetic and non- Diabetic Haemodialysis patients. - How differ dyslipidemia types among Diabetic and non- Diabetic in Haemodialysis patients. (Qualitative difference).

Clinical Trial Description

Diabetes mellitus (DM) is a metabolic disease , a consequence of defects in insulin action, secretion, or both, and there are complications associated with it, such as nephropathy, retinopathy, neuropathy, cardiovascular complications ,cerebrovascular and peripheral arterial disease. Diabetic nephropathy, which occurs in about one third of type 2 diabetic patients, is the most common factor leading to end-stage renal disease (ESRD) . A very common metabolic abnormality associated with diabetes is dyslipidemia, which is characterized by a spectrum of quantitative and qualitative changes in lipids and lipoproteinsSeveral previous studies have pursued linking blood glucose levels to serum lipid activities. The etiology of dyslipidemia appears to be centered on the increased large TAG-rich very low-density lipoprotein-cholesterol (VLDL-C) and its impaired clearance. American diabetic association (ADA) defines dyslipidemia as hypercholesterolemia ≥200 mg/dl of serum total cholesterol, hypertriglyceridemia ≥150 mg/dl of serum triglyceride, reduced high density lipoprotein cholesterol (HDL-C) <40 mg/dl for men and <50 mg/dl for women, elevated low density lipoprotein cholesterol (LDL-C) ≥70 mg/dl and high TC to HDL-C ratio of ≥4.5. Normal plasma lipids and lipoprotein metabolism is critical for cellular cholesterol homeostasis and protection against atherosclerosis, renal disease and other complication . A study found that people with high blood pressure and overweight or obesity have a higher risk of developing dyslipidemia ,Early detection and effective control of blood lipid levels can reduce the morbidity and mortality of CVD in patients with DM. Therefore, it is important to determine the factors associated with dyslipidemia. ;

Study Design

Related Conditions & MeSH terms

Dyslipidemias

Clinical Trial Details

NCT number	NCT06401122
Study type	Observational
Source	Assiut University
Contact	dina A. Abudeif, doctor
Phone	+201141210144
Email	dinaaliabudeif7@gmail.com
Status	Not yet recruiting
Phase
Start date	June 1, 2024
Completion date	December 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04591808` - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia	Phase 3
Completed	`NCT04894318` - The Effect Of Low-Fat And Low-Cholesterol Dietary Intervention On LDL Sub-Groups In Turkısh Dyslipidemic Patients	N/A
Completed	`NCT04862962` - Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
Completed	`NCT04052594` - A Study of LY3475766 in Healthy Participants	Phase 1
Active, not recruiting	`NCT04270084` - Metabolic Optimization Through Diet/Lifestyle Improvements For Youth	N/A
Completed	`NCT03241121` - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome	N/A
Completed	`NCT04516291` - A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)	Phase 2
Completed	`NCT03170752` - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)	N/A
Completed	`NCT05124847` - TREating Pediatric Obesity	N/A
Completed	`NCT04186780` - Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study	N/A
Not yet recruiting	`NCT03674333` - Effect of Adding Folic Acid on Lipid Parameters in Population With Dyslipidemias	N/A
Not yet recruiting	`NCT06159543` - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes	N/A
Terminated	`NCT01697735` - The Therapeutic Effects of Statins and Berberine on the Hyperlipemia	Phase 4
Completed	`NCT00362908` - Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome	N/A
Completed	`NCT00455325` - Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)	Phase 2
Completed	`NCT00644709` - A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)	Phase 4
Recruiting	`NCT05624658` - Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS	N/A
Recruiting	`NCT03988101` - Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event	Phase 4
Recruiting	`NCT06024291` - Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial	N/A
Completed	`NCT01218204` - A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparison of Dyslipidemia Among Diabetics Versus Non Diabetics in Haemodialysis Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms